Research and Development, ITB-Med AB, Stockholm, Sweden; Endocrine and Sarcoma Surgery Unit, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
Auto-generated profile, based on publicly available information
Filip Cvetkovski
Research and Development, ITB-Med AB, Stockholm, Sweden; Endocrine and Sarcoma Surgery Unit, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
Combined antigen-specific T cell receptor stimulation and costimulation are needed for complete T cell activation. Belatacept and Abatacept are non-depleting fusion proteins blocking CD28/B7 costimulation, while siplizumab is a depleting anti-CD2 IgG1 monoclonal antibody targeting CD2/CD58 costimulation. Herein, the effect of siplizumab combination therapy with Abatacept or Belatacept on T cell alloreactivity in mixed lymphocyte reaction (MLR) was investigated. In contrast to monotherapy, the combination of siplizumab with Belatacept or Abatacept induced near complete suppression of T cell proliferation and increased the potency of siplizumab-mediated T cell inhibition. Furthermore, dual targeting of CD2 and CD28 costimulation enhanced the selective depletion of memory T cells when compared to monotherapy. While siplizumab monotherapy leads to significant regulatory T cell (Treg) enrichment, high doses of CTLA4-Ig in the combination therapy reduced this effect. These results support the clinical evaluation of dual costimulation blockade, combining siplizumab with Abatacept or Belatacept, for the prophylaxis of organ transplant rejection and improvement of long-term outcomes following transplantation. Ongoing investigative research will elucidate if other forms of siplizumab-based dual costimulatory blockade may be able to induce similarly strong inhibition of T cell activation while still allowing for enrichment of regulatory T cells.